Mecasermin (INN) (trade name Increlex) is recombinant human insulin-like
growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure
May 2, 2016 ... Easy to read patient leaflet for mecasermin. Includes indications, proper use,
special instructions, precautions, and possible side effects.
Apr 1, 2015 ... Mecasermin injection is a man-made version of insulin-like growth factor-1 (IGF-1
) hormone. IGF-1 is produced in the liver and plays an ...
May 16, 2007 ... Mecasermin contains recombinant-DNA-engineered human insulin-like growth
factor-1 (rhIGF-1). IGF-1 consists of 70 amino acids in a single ...
1.1 Severe Primary IGF-1 Deficiency (Primary IGFD) INCRELEX® (mecasermin [
rDNA origin] injection) is indicated for the treatment of: growth failure in .
Mecasermin (Increlex®). [Developed, December 2006; Revised, May 2007; May
2010; June 2010; February 2012; December 2013]. MEDICAID DRUG USE ...
Aetna considers mecasermin (Increlex) and mecasermin rinfabate (Iplex)*
medically necessary for the treatment of growth failure in children with severe
INCRELEX (mecasermin) is recombinant human insulin-like growth factor-1 ...
Mecasermin was granted orphan status in the EU for “Treatment of growth ...
Drug information on Increlex (mecasermin), includes drug pictures, side effects,
drug interactions, directions for use, symptoms of overdose, and what to avoid.
Mecasermin [rDNA origin] injection (Increlex) is used for the long-term treatment
of growth failure in children with severe primary insulin-like growth factor (IGF)-1